Ataraxis AI

Ataraxis AI

AI-driven diagnostic tests enhancing precision medicine with rapid, personalized cancer prognostics.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor

€0.0

round
*

$20.4m

Series A
Total Funding000k
More about Ataraxis AI
Made with AI
Edit

Ataraxis AI is a precision medicine company focused on revolutionizing cancer diagnostics through advanced AI technology. With a recent emergence from stealth mode and backed by $4 million in seed funding, Ataraxis AI has introduced its first product, Ataraxis Breast, an AI-native prognostic test for breast cancer. This test is designed to significantly improve the prediction of patient outcomes, allowing for more precise and personalized treatment plans. Operating in the healthcare sector, particularly in oncology, Ataraxis AI serves physicians and healthcare providers by offering rapid diagnostic results within one business day. The company's business model revolves around providing these AI-powered diagnostic tests, which are accessible through a physician portal or delivered directly to clinicians. By leveraging AI, Ataraxis AI aims to set a new standard in molecular diagnostics, traditionally the benchmark for personalized treatment selection. Keywords: AI, precision medicine, cancer diagnostics, breast cancer, prognostic test, oncology, personalized treatment, healthcare, molecular diagnostics, rapid results.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo